Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) has a beta value of 1.85 and has seen 3.18 million shares traded in the last trading session. The ZNTL stock price is -652.92% off its 52-week high price of $18.07 and 11.25% above the 52-week low of $2.13. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.65 million shares traded. The 3-month trading volume is 1.56 million shares.
The consensus among analysts is that Zentalis Pharmaceuticals Inc (ZNTL) is Buy stock at the moment, with a recommendation rating of 2.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 5 out of 10 have rated it as a Hold, with 5 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.74.
Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) trade information
Over the past 30 days, the shares of Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) have changed -25.47%. Short interest in the company has seen 5.08 million shares shorted with days to cover at 3.46.
Wall Street analysts have a consensus price target for the stock at $10, which means that the shares’ value could jump 76.0% from current levels. The projected low price target is $4.0 while the price target rests at a high of $55.0. In that case, then, we find that the current price level is -2191.67% off the targeted high while a plunge would see the stock gain -66.67% from current levels.
Zentalis Pharmaceuticals Inc (ZNTL) estimates and forecasts
Figures show that Zentalis Pharmaceuticals Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -46.31% over the past 6 months, with this year growth rate of 44.52%, compared to 16.40% for the industry. Revenue growth from the last financial year stood is estimated to be 0.00%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -50.05% over the past 5 years. Earnings growth for 2025 is a modest 43.70% while over the next 5 years, the company’s earnings are expected to increase by 16.81%.
ZNTL Dividends
Zentalis Pharmaceuticals Inc is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL)’s Major holders
Insiders own 12.87% of the company shares, while shares held by institutions stand at 97.97% with a share float percentage of 112.44%. Investors are also buoyed by the number of investors in a company, with Zentalis Pharmaceuticals Inc having a total of 188.0 institutions that hold shares in the company. The top two institutional holders are MATRIX CAPITAL MANAGEMENT COMPANY, LP with over 13.96 million shares worth more than $57.1 million. As of 2024-06-30, MATRIX CAPITAL MANAGEMENT COMPANY, LP held 19.6902% of shares outstanding.
The other major institutional holder is FMR LLC, with the holding of over 8.68 million shares as of 2024-06-30. The firm’s total holdings are worth over $35.49 million and represent 12.2383% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund and Mutual Fund Ser Tr-Eventide Gilead Fund . As of Sep 30, 2024 , the former fund manager holds about 6.94% shares in the company for having 4.95 shares of worth $11.88 million while later fund manager owns 3.58 shares of worth $8.6 million as of Sep 30, 2024 , which makes it owner of about 5.03% of company’s outstanding stock.
